Pralsetinib (BioDeep_00000839623)

   


代谢物信息卡片


Pralsetinib

化学式: C27H32FN9O2 (533.2662864)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
InChI: InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
D000970 - Antineoplastic Agents

同义名列表

1 个代谢物同义名

Pralsetinib



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yunong Zhang, Shinpan Chan, Rui He, Yiling Liu, Xiaojuan Song, Zheng-Chao Tu, Xiaomei Ren, Yang Zhou, Zhang Zhang, Zhen Wang, Fengtao Zhou, Ke Ding. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions. European journal of medicinal chemistry. 2022 Dec; 244(?):114862. doi: 10.1016/j.ejmech.2022.114862. [PMID: 36308779]
  • Yang Zhou, Shuang Xiang, Fang Yang, Xiaoyun Lu. Targeting Gatekeeper Mutations for Kinase Drug Discovery. Journal of medicinal chemistry. 2022 12; 65(23):15540-15558. doi: 10.1021/acs.jmedchem.2c01361. [PMID: 36395392]
  • Yaogeng Wang, Rolf W Sparidans, Sander Potters, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacological research. 2021 10; 172(?):105850. doi: 10.1016/j.phrs.2021.105850. [PMID: 34450308]
  • J J Lin, S V Liu, C E McCoach, V W Zhu, A C Tan, S Yoda, J Peterson, A Do, K Prutisto-Chang, I Dagogo-Jack, L V Sequist, L J Wirth, J K Lennerz, A N Hata, M Mino-Kenudson, V Nardi, S-H I Ou, D S-W Tan, J F Gainor. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 12; 31(12):1725-1733. doi: 10.1016/j.annonc.2020.09.015. [PMID: 33007380]
  • Rahime Şentürk, Yaogeng Wang, Alfred H Schinkel, Jos H Beijnen, Rolf W Sparidans. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Jun; 1147(?):122131. doi: 10.1016/j.jchromb.2020.122131. [PMID: 32416592]